{
    "clinical_study": {
        "@rank": "163218", 
        "arm_group": {
            "arm_group_label": "aSAH patients", 
            "description": "Patients suffering from aneurysmal subarachnoid haemorrhage"
        }, 
        "biospec_descr": {
            "textblock": "-  Blood samples\n\n        -  Cerebrospinal fluid samples\n\n        -  Microdialysate samples (from the extracellular fluid of the brain)\n\n        -  Tissue samples"
        }, 
        "brief_summary": {
            "textblock": "Subarachnoidal hemorrhage (SAH) is a cause of long-term disability and death. Annually about\n      1000 people in Finland suffer from SAH, their average age being under 50 years. SAH has a\n      mortality rate of 12 % acutely and 40 % of patients die within a month from admission to\n      hospital. In addition, 30 % of the surviving patients remain with neurological deficits.\n      Most survivors of the primary insult suffer from secondary injury during the first 2-3 weeks\n      from the insult.\n\n      Despite the advances in neurosurgical and -radiological techniques and intensive care, the\n      mortality and morbidity rates in SAH have not changed in recent years. There is still only\n      limited understanding of the mechanisms of secondary insults causing brain injury after SAH.\n\n      In this study the investigators are aiming to clarify the timescale and mechanisms\n      contributing to the secondary insults. The investigators also explore usability of novel\n      biomarkers to guide treatment of the patients suffering from SAH."
        }, 
        "brief_title": "SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Aneurysmal Subarachnoid Hemorrhage", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Subarachnoid Hemorrhage", 
                "Brain Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subarachnoidal hemorrhage (SAH) is a cause of long-term disability and death. Annually about\n      1000 people in Finland suffer from SAH, their average age being under 50 years. SAH has a\n      mortality rate of 12 % acutely and 40 % of patients die within a month from admission to\n      hospital. In addition, 30 % of the surviving patients remain with neurological deficits.\n      Most survivors of the primary insult suffer from secondary injury during the first 2-3 weeks\n      from the insult.\n\n      Despite the advances in neurosurgical and -radiological techniques and intensive care, the\n      mortality and morbidity rates in SAH have not changed in recent years. There is still only\n      limited understanding of the mechanisms of secondary insults causing brain injury after SAH.\n\n      In this study the investigators are aiming to clarify the timescale and mechanisms\n      contributing to the secondary insults. The investigators also explore usability of novel\n      biomarkers to guide treatment of the patients suffering from SAH."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  aneurysmal subarachnoid haemorrhage\n\n        Exclusion Criteria:\n\n          -  age under 18 years\n\n          -  pregnant\n\n          -  moribund patient"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients suffering from aneurysmal subarachnoid haemorrhage"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02026596", 
            "org_study_id": "TampereUH"
        }, 
        "intervention": [
            {
                "arm_group_label": "aSAH patients", 
                "intervention_name": "Magnetic resonance imaging", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "aSAH patients", 
                "description": "Is inserted only when invasive intracranial pressure monitoring is required. The same route with pressure probe is used for insertion.", 
                "intervention_name": "Cerebral microdialysis catheter insertion", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "subrachnoid hemorrhage", 
            "secondary brain injury"
        ], 
        "lastchanged_date": "January 1, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tampere", 
                    "country": "Finland", 
                    "state": "L\u00e4nsi-Suomen l\u00e4\u00e4ni", 
                    "zip": "33521"
                }, 
                "name": "Tampere University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Marika Ala-Peijari, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jukka Peltola, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kai Lehtim\u00e4ki, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ville Jalkanen, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hanna Heinonen, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Heikki Kiiski, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Juha \u00d6hman, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jaakko L\u00e5ngsj\u00f6, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sirpa Savilahti, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Prasun Dastidar, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jyrki Tenhunen, MD, PhD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_groups": "1", 
        "official_title": "Observational Study on Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage", 
        "overall_contact": {
            "email": "jyrki.tenhunen@surgsci.uu.se", 
            "last_name": "Jyrki Tenhunen, MD, PhD"
        }, 
        "overall_contact_backup": {
            "email": "heikki.kiiski@uta.fi", 
            "last_name": "Heikki Kiiski, MD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Finland: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Neuroradiological imaging (CT/MRI) is performed when clinically indicated and at 2 weeks after primary insult.", 
            "measure": "Neuroradiologically confirmed secondary injury lesions", 
            "safety_issue": "No", 
            "time_frame": "up to 2 weeks after the primary insult"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02026596"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tampere University Hospital", 
            "investigator_full_name": "Jyrki Tenhunen", 
            "investigator_title": "Docent", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Neurological outcome is evaluated with modified Rankin Scale at 6 months.", 
            "measure": "Neurological outcome of the patient", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Tampere University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tampere University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "6 Months", 
        "verification_date": "January 2014"
    }
}